Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

NCT03717155 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Avelumab
DRUG: Cetuximab
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Merck KGaA, Darmstadt, Germany